Sino Biopharmaceutical Initiates Phase III Trial of LM-302 ADC Combined with Anti-PD-1 for CLDN18.2-Positive Gastric Cancer
Sino Biopharmaceutical Ltd (HKG: 1177) has announced the enrollment of the first patient in a...
Mabwell Bioscience Secures Second NMPA Approval for Denosu, China’s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China’s...
CSPC Pharmaceutical Secures NMPA Clinical Trial Approval for SYS6051, a Tissue Factor-Targeted ADC for Advanced Solid Tumors
CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that China’s National Medical Products Administration (NMPA)...
Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment
Ty Biotech (HKG: 1332) has announced a strategic cooperation agreement with Shenzhen University to commercialize...
Insilico Medicine and Ancestor Cell Forge AI-Stem Cell Alliance to Accelerate Exosome Therapeutics Development
Insilico Medicine (HKG: 3696), a leading artificial intelligence (AI) drug discovery platform, has announced a...
Luye Pharma Initiates Phase II Trial of LY03017 for Alzheimer’s-Associated Psychosis in China Following US Clinical Clearance
Luye Pharma Group Limited (HKG: 2186) has announced the initiation of a Phase II clinical...
GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235
GlaxoSmithKline plc (GSK, NYSE: GSK) has completed its acquisition of 35Pharma Inc., a Canadian biopharmaceutical...
Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision
Shionogi & Co., Ltd. (TYO: 4507) has announced the completion of its first corporate venture...
Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers
Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Boehringer Ingelheim (BI) have announced a strategic clinical...
3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem
3SBio Inc. (HKG: 1530) and Hangzhou Tigermed Consulting Co., Ltd. (SHE: 300347, HKG: 3347), China’s...
Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment
Daiichi Sankyo Co., Ltd. (TYO: 4568) has announced an agreement to transfer all shares of...
Bayer AG Secures NMPA Approval for Hyrnuo (Sevabertinib) to Treat HER2-Mutant NSCLC in China
Bayer AG (ETR: BAYN) announced that China’s National Medical Products Administration (NMPA) has granted marketing...
Johnson & Johnson Partners with Shanghai Pharmaceuticals for Exclusive Promotion of Paliperidone Palmitate Long-Acting Injection in China
Johnson & Johnson (J&J, NYSE: JNJ) has entered into an exclusive marketing promotion agreement with...
Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Transform Healthcare Operations
Novo Nordisk (NYSE: NVO) announced on April 14, 2026, a strategic partnership with OpenAI that...
Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders
Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory...
China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives
The State Council released the “Opinions on Improving the Drug Pricing Mechanism” this week, introducing...
Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes
Gan & Lee Pharmaceuticals (SHA: 603087) announced the first subject dosing in a Phase III...
AC Immune and Eli Lilly Amend 2018 Alzheimer’s Partnership to Advance Tau Morphomer Candidates
AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised...
Autobio Diagnostics Expands Global IVD Footprint with Dual Vietnam Partnerships
Autobio Diagnostics Co., Ltd. (SHA: 603658) announced this week it has executed separate strategic partnership...
Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma
Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with...